Is Pfizer's established drugs' decline in China the ‘canary in the coalmine?’

Big Pharma has been able to count on China to jack up growth for the last several years, but in the second quarter one drugmaker—Pfizer's Upjohn unit—wasn't so fortunate. Is that an ill omen for the rest of multinational pharma? Yes and no, one analyst figures.